News

The completion of the Human Genome project has ushered in a new era in our understanding of cancer.

Glofitimab is the first and only CD20xCD3 T-cell engaging bispecific antibody approved for the treatment of relapsed/refractory DLBCL.

Mohamad Mohty, MD, PhD, discusses the growing role of bispecific antibodies for the treatment of multiple myeloma.

Mark J. Levis, MD, PhD, discusses the takeaways from the phase 3 BMT CTN 1506/MORPHO trial which evaluated maintenance gilteritinib after allogeneic stem cell transplant in patients with FLT3-ITD–positive acute myeloid leukemia.

Though the radioligand therapy lutetium Lu 177 vipivotide tetraxetan was approved in 2022 for PSMA-avid patients, several practical considerations have limited its use among patients with prostate cancer.

Data from the phase 3 NAPOLI 3 trial have led the FDA to accept a supplemental new drug application for NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma

John M. Burke, MD, turns to ChatGPT to uncover what artificial intelligence may do for hematologists/oncologists.

In an interview with Targeted Oncology, Se-Hoon Lee, MD, PhD, discussed long-term follow-up data from the CHRYSALIS trial in patients with EGFR-mutated advanced non–small cell lung cancer.

In the phase 2 KEYNOTE-942 trial, the 18-month distant metastasis-free survival rate was 91.8% with mRNA-4157 plus pembrolizumab vs 76.8% with pembrolizumab alone.

A newly authorized phase 1b study will evaluate the safety and efficacy of the continuous delivery of lenalidomide among patients with multiple myeloma.

According to phase 2 study results, the combination of prolgolimab, bevacizumab and platinum doublet chemotherapy showed promising efficacy and an adequate safety profile in cervical cancer.

Though scientific advances have been encouraging in the thyroid cancer space, there is much more work to be done to figure out exactly how to tailor the right therapy, or combination of therapies, for individual patients.

The phase 2a portion of a study will evaluate fostrox as a triplet in earlier lines of immunotherapy combinations for patients with hepatocellular carcinoma.

The FDA has requested additional time to assess the analyses of previously submitted data from the phase 3 DeFi trial of nirogacestat in desmoid tumors, leading to an extension of the Prescription Drug User Fee Act decision date.

In part C of the phase 2 SGN35-027 trial evaluating brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine in patients with classical Hodgkin lymphoma, fewer than half of patients developed primarily low-grade peripheral neuropathy, and no cases of febrile neutropenia were observed.

Bhagirathbhai R. Dholaria, MBBS, discusses updated findings from the TRIMM-2 trial of talquetamab and daratumumab for the treatment of relapsed/refractory multiple myeloma.

Promising data were revealed with nelarabine, intensive L-asparaginase, and protracted intrathecal therapy among patients aged 25 years and younger with T-cell acute lymphoblastic leukemia.

The use of polatuzumab vedotin in place of vincristine in R-mini-CHOP may lead to an increase in gastrointestinal adverse events in frail patients with diffuse large B-cell lymphoma.

Data from the phase 3 CAPItello-291 trial of capivasertib plus fulvestrant in HR-positive, HER2-negative locally advanced or metastatic breast cancer have led the FDA to grant priority review to the new drug application for the combination.

Yael Cohen, MD, discusses the main safety findings from the phase 1/2 RedirecTT-1 trial, which is evaluating the combination of teclistamab-cqyv and talquetamab for the treatment of patients with relapsed/refractory multiple myeloma.

In patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease after hematopoietic stem cell transplant, treatment with gilteritinib elicited a 48% reduction vs patients without detectable MRD.

In an interview with Targeted Oncology, Jonathan C. Trent, MD, PhD, discussed primary and offshoot analysis data from the INTRIGUE study of patients with GIST.

Findings from the phase 3 PhALLCON trial show that ponatinib plus reduced-intensity chemotherapy could be a new standard of care for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

The Association for Clinical Oncology has provided recommendations to the FDA for its draft guidance, which reflects a strong preference for randomized controlled trials.

Preliminary findings from arm 4 of the phase 2 MANIFEST trial show hematologic response and symptom improvement with pelabresib in high-risk essential thrombocythemia that is refractory or intolerant to hydroxyurea.

Treatment with maintenance daratumumab, with or without pomalidomide, led to a median PFS of 28.5 months in patients with relapsed multiple myeloma after undergoing salvage autologous hematopoietic stem cell transplantation.

Patients aged 80 years or older and/or considered frail who received acalabrutinib for chronic lymphocytic leukemia experienced toxicities consistent with prior trials.

In patients with relapsed/refractory multiple myeloma who were previously treated with lenalidomide, the combination of daratumumab, ixazomib, and dexamethasone led to improved overall response rates.

The addition of acalabrutinib to bendamustine and rituximab met tolerability and safety end points in a phase 1b trial, as well as promising efficacy results in patients with either treatment-naive or relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses what led to the start of the phase 3 BRUIN MCL-321 trial for patients with mantle cell lymphoma.